Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: A single-centre experience

European Journal of Haematology

Volumn 66, Issue 1, 2001, Pages 43-49

  Nachbaur, D ^a,d   Oberaigner, W ^b   Fritsch, E ^c   Nussbaumer, W ^c   Gast, G ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Cancer Registry of Tyrol   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d Clinic of Internal Medicine   (Austria)

Author keywords

Graft versus lymphoma (GVL) effect; Hodgkin's disease (HD); Non Hodgkin's lymphoma (NHL); Stem cell transplantation (SCT)

Indexed keywords

LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; AGED; AUSTRIA; BONE MARROW; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRAFT VS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; L-LACTATE DEHYDROGENASE; LIFE TABLES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0035142486     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.00300.x     Document Type: Article

References (34)

1. Bone marrow transplantation in the treatment of patients with lymphoma
2. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediategrade or high-grade non-Hodgkin's lymphoma
3. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who are still responsive to conventional-dose chemotherapy
4. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation
5. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
6. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis
7. Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle
8. Results of high-dose therapy and autolgous bone marrow/stem cell transplantation during remission in poor-risk intermediate and high-grade lymphoma: International Index high and high-intermediate risk group
9. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2
10. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: Updated results of the Utrecht experience
11. Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease
12. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management
13. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma
14. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin
15. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma
16. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma
17. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy
18. Prospective comparative trial of autologous versus allogeneic marrow transplantation in patients with non-Hodgkin's lymphoma
19. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma
20. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group Registry Data
21. Evidence for a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation
22. Updated Kiel classification for lymphomas
23. The pathology and nomenclature of Hodgkin's disease
24. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy
25. CD34+ selected autologous peripheral blood stem cell transplantation (PBSCT) in patients with poor-risk hematological malignancies and solid tumors. A single centre experience
26. Non-parametric estimation for incomplete observations
27. EBMT Statistical guidelines
28. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: Clinical and molecular follow-up
29. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma
30. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect
31. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma
32. Progressive disease after high-dose therapy and autologoustransplantation for lymphoid malignanciy: Clinical cours and patient follow-up
33. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
34. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies